Eliminating Tuberculosis and Tuberculosis-HIV Co-Disease in the 21st Century: Key Perspectives, Controversies, Unresolved Issues, and Needs
Opportunities and Challenges for Cost-Efficient Implementation of New Point-of-Care Diagnostics for HIV and Tuberculosis
Renewed Focus on Tuberculosis Holds Promise for New Treatments FDA approved rifampin for the treatment of tuberculosis (TB) in 1971, the same year Intel Corporation invented the first microproc
Tucson institute plays critical cancer role Re: the April 19 article “Vast study advances breast cancer fight.”
ACRO Testifies Before FDA on Clinical Trial Modernization WASHINGTON–(BUSINESS WIRE)– The Association of Clinical Research Organizations (ACRO) today provided the FDA with a nu
C-Path Initiative’s Work on Personalized Medicine Starts to Get Results The Critical path Institute (C-Path), the US Food and Drug Administration (FDA)-supported public-private initiative working to adv
